Osaka, Japan, Japan · Est. 1781 · 47,000 employees
Takeda is a global biopharmaceutical company focused on developing treatments in oncology, gastroenterology, neuroscience, and rare diseases.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 17 drugs with upcoming expirations
Pipeline
By Phase
31 drugs in development
By Therapeutic Area
top 6
R&D Momentum
87/100
Pipeline Velocity
63/100
Trial Completion Rate
85/100
Pipeline Concentration
14/100
Pipeline Freshness
71/100
Strategic Signals
Activity
Last 14 days
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo
A Phase 2, Open-label, Proof-of-Concept Study to Investigate the Efficacy, Safety, and Tolerability of TAK-411 in Adult Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (The CASCA Study)
A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-Controlled Induction Study Followed by an Open-label Extension Period to Evaluate the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Subjects in China With Moderately to Severely Active Crohn's Disease
A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
A Phase 1/2 Study of the Oral EGFR/HER2 Inhibitor TAK-788 in Japanese Non-Small Cell Lung Cancer Patients
Epidemiology of Narcolepsy Type 1 and Type 2 in Spain
A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia
A Randomized, Double-blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once-Daily Oral Administration of Vortioxetine in Japanese Pediatric Patients 12 to 17 Years of Age With Major Depressive Disorder (MDD)
Details
Company Overview
$55.0B
Mkt Cap
$32.0B
Revenue
—
Cash
Therapeutic Focus
Pipeline
Regulatory
Iclusig — ICLUSIG
Application NDA203469 (NDA)
Iclusig — ICLUSIG
Application NDA203469 (NDA)
Livtencity — LIVTENCITY
Application NDA215596 (NDA)
Rozerem — ROZEREM
Application NDA021782
Lialda — LIALDA
Application NDA022000
Exkivity — EXKIVITY
Application NDA215310 (NDA)
Lialda — LIALDA
Application NDA022000
Lialda — LIALDA
Application NDA022000
Cedazuridine — INQOVI
Application NDA212576
Nesina — NESINA
Application NDA022271
Elunate — FRUZAQLA
Application NDA217564 (NDA)
Lialda — LIALDA
Application NDA022000
Entyvio — ENTYVIO
Application BLA761133 (BLA)
Nesina — NESINA
Application NDA022271
Uloric — ULORIC
Application NDA021856
Vyvanse — ARYNTA
Application NDA219847 (NDA)
Vyvanse — ARYNTA
Application NDA219847 (NDA)
Lialda — LIALDA
Application NDA022000
Mimrylo — MIMRYLO
Application NDA220605 (NDA)
Cedazuridine — INQOVI
Application NDA212576
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)